Showing results (31-40 of 133) with videos related to
Sort By:
Pageof 14
BMC Pulmonary Medicine|November 17, 2020
Rapidly progressive metastatic cholangiocarcinoma in a postpartum patient with cystic fibrosis: a case reportSara W Carson, Kelly E Craven, David Nauen, et al.JCI Insight|December 20, 2019
Multipanel mass cytometry reveals anti-PD-1 therapy-mediated B and T cell compartment remodeling in tumor-draining lymph nodesWon Jin Ho, Mark Yarchoan, Soren Charmsaz, et al.Plos One|July 7, 2011
Chronic losartan administration reduces mortality and preserves cardiac but not skeletal muscle function in dystrophic miceLawrence T Bish, Mark Yarchoan, Meg M Sleeper, et al.Cancers|March 14, 2026
Global Re-Analysis Confirms Absence of the <i>DNAJB1</i>::<i>PRKACA</i> Fusion in Hepatoblastoma. Comment on Fleifil et al. DNAJB1-PKAc Kinase Is Expressed in Young Patients with Pediatric Liver Cancers and Enhances Carcinogenic Pathways. <i>Cancers</i> 2025, <i>17</i>, 83Waqar Arif, Sanford M Simon, Allison F O'Neill, et al.Cancer Immunology Research|August 14, 2021
Context-Dependent Immunomodulatory Effects of MEK Inhibition Are Enhanced with T-cell Agonist TherapyLauren Dennison, Amanda Ruggieri, Aditya Mohan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2017
Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful ActivityValsamo Anagnostou, Mark Yarchoan, Aaron R Hansen, et al.Nature Reviews. Clinical Oncology|February 29, 2024
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinomaJosep M Llovet, Roser Pinyol, Mark Yarchoan, et al.Cell|April 17, 2026
Hallmarks of liver cancer: Therapeutic implicationsJosep M Llovet, Roser Pinyol, Silvia Affo, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2020
Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression AnalysisArsen Osipov, Su Jin Lim, Aleksandra Popovic, et al.Plos One|November 1, 2019
MEK inhibition suppresses B regulatory cells and augments anti-tumor immunityMark Yarchoan, Aditya A Mohan, Lauren Dennison, et al.Pageof 14